A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia.

Trial Profile

A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Solithromycin (Primary) ; Levofloxacin
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Sponsors Cempra Pharmaceuticals
  • Most Recent Events

    • 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
    • 31 Mar 2012 Results to be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2012)
    • 18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top